1,3-dimethyl-7-(3-methylbut-2-enyl)-8-[[(2R)-pyrrolidin-2-yl]methoxy]purine-2,6-dione | 1443216-82-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 1,3-dimethyl-7-(3-methylbut-2-enyl)-8-[[(2R)-pyrrolidin-2-yl]methoxy]purine-2,6-dione
• CAS: 1443216-82-7
• 化学式: C₁₇H₂₅N₅O₃
• 分子量: 347.417
• InChiKey: CVJWBMIJZVYAIY-GFCCVEGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  79.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  tert-butyl (R)-2-(((1,3-dimethyl-7-(3-methylbut-2-en-1-yl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)oxy)methyl)pyrrolidine-1-carboxylate 在 甲烷磺酸 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 、 水 为溶剂， 生成 1,3-dimethyl-7-(3-methylbut-2-enyl)-8-[[(2R)-pyrrolidin-2-yl]methoxy]purine-2,6-dione
  参考文献：
  名称：

  Integrated Synthesis and Testing of Substituted Xanthine Based DPP4 Inhibitors: Application to Drug Discovery

  摘要：

  A novel integrated discovery platform has been used to synthesize and biologically assay a series of xanthine-derived dipeptidyl peptidase 4 (DPP4) antagonists. Design, synthesis, purification, quantitation, dilution, and bioassay have all been fully integrated to allow continuous automated operation. The system has been validated against a set of known DPP4 inhibitors and shown to give excellent correlation between traditional medicinal chemistry generated biological data and platform data. Each iterative loop of synthesis through biological assay took two hours in total, demonstrating rapid iterative structure-activity relationship generation.

  DOI：

  10.1021/ml400171b

文献信息

• Integrated Synthesis and Testing of Substituted Xanthine Based DPP4 Inhibitors: Application to Drug Discovery
  作者：Werngard Czechtizky、Jüergen Dedio、Bimbisar Desai、Karen Dixon、Elizabeth Farrant、Qixing Feng、Trevor Morgan、David M. Parry、Manoj K. Ramjee、Christopher N. Selway、Thorsten Schmidt、Gary J. Tarver、Adrian G. Wright

  DOI：10.1021/ml400171b

  日期：2013.8.8

  A novel integrated discovery platform has been used to synthesize and biologically assay a series of xanthine-derived dipeptidyl peptidase 4 (DPP4) antagonists. Design, synthesis, purification, quantitation, dilution, and bioassay have all been fully integrated to allow continuous automated operation. The system has been validated against a set of known DPP4 inhibitors and shown to give excellent correlation between traditional medicinal chemistry generated biological data and platform data. Each iterative loop of synthesis through biological assay took two hours in total, demonstrating rapid iterative structure-activity relationship generation.